A mass spectrometric method for quantification of tryptophan-derived uremic solutes in human serum
Main Article Content
Keywords
uremic solutes, mass spectrometry, indoxyl sulfate, kynurenine
Abstract
In addition to various physiologic roles, emerging evidence strongly points to pathogenic roles of tryptophan and of its metabolites, especially in diseases such as renal failure. Accurate estimation of levels of these metabolites in blood is important to mechanistically probe their contribution to disease pathogenesis, while clinically, such a panel can be used to risk stratify patients for a clinical phenotype. Herein, we describe a comprehensive liquid chromatography-mass spectrometry (LC/MS)-based method to determine the level of tryptophan and its metabolites (kynurenine, kynurenic acid, xanthurenic acid, anthranilic acid, indoxyl sulfate and indoxyl acetate). Human sera samples were processed through a C18 column followed by application of a binary gradient and quantitation by MS/MS. The linearity, lower limit of detection, inter- and intraassay variabilities and recovery were determined, yielding a precise, reproducible method for all the metabolites. Unlike previous studies, we further validated these methods in a well-characterized set of human sera from end stage renal disease patients compared to age-, gender- and ethnic-background matched human controls. Overall, we report an optimized LC/MS-based estimation of a comprehensive panel of tryptophan-derived metabolites with quality features within FDA standards, underscoring their readiness for translational use.
Downloads
Download data is not yet available.
Metrics
Metrics Loading ...
References
1. Michael, A.F., et al., Tryptophan Metabolism in Man. J Clin Invest, 1964. 43: p. 1730-46.
2. Vanholder, R., et al., Uremic toxicity: present state of the art. Int J Artif Organs, 2001. 24(10): p. 695-725.
3. Yao, K., et al., Tryptophan metabolism in animals: important roles in nutrition and health. Front Biosci (Schol Ed), 2011. 3: p. 286-97.
4. Pawlak, K., et al., Kynurenine, quinolinic acid--the new factors linked to carotid atherosclerosis in patients with end-stage renal disease. Atherosclerosis, 2009. 204(2): p. 561-6.
5. Oxenkrug, G.F., Metabolic syndrome, age-associated neuroendocrine disorders, and dysregulation of tryptophan-kynurenine metabolism. Ann N Y Acad Sci, 2010. 1199: p. 1-14.
6. Nguyen, N.T., et al., Aryl hydrocarbon receptor and kynurenine: recent advances in autoimmune disease research. Front Immunol, 2014. 5: p. 551.
7. Kawasaki, H., et al., A tryptophan metabolite, kynurenine, promotes mast cell activation through aryl hydrocarbon receptor. Allergy, 2014. 69(4): p. 445-52.
8. Shivanna, S., et al., The Aryl Hydrocarbon Receptor is a Critical Regulator of Tissue Factor Stability and an Antithrombotic Target in Uremia. J Am Soc Nephrol, 2016. 27(1): p. 189-201.
9. Shashar, M., J. Francis, and V. Chitalia, Thrombosis in the uremic milieu--emerging role of "thrombolome". Semin Dial, 2015. 28(2): p. 198-205.
10. Pawlak, D., et al., Accumulation of toxic products degradation of kynurenine in hemodialyzed patients. Int Urol Nephrol, 2001. 33(2): p. 399-404.
11. Itoh, Y., et al., Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production. Anal Bioanal Chem, 2012. 403(7): p. 1841-50.
12. Chen, Y., et al., RRLC-MS/MS-based metabonomics combined with in-depth analysis of metabolic correlation network: finding potential biomarkers for breast cancer. Analyst, 2009. 134(10): p. 2003-11.
13. EMA. Guidance for industry: bioanalytical method validation. US Department of health and human service, US FDA, Rockville, MD USA. .
14. Zhu, W., et al., Quantitative profiling of tryptophan metabolites in serum, urine, and cell culture supernatants by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem, 2011. 401(10): p. 3249-61.
15. Fuertig, R., et al., LC-MS/MS-based quantification of kynurenine metabolites, tryptophan, monoamines and neopterin in plasma, cerebrospinal fluid and brain. Bioanalysis, 2016. 8(18): p. 1903-17.
16. Meyer, T.W., et al., The clearance of protein-bound solutes by hemofiltration and hemodiafiltration. Kidney Int, 2005. 68(2): p. 867-77.
17. Manni, A., et al., Bioavailability of albumin-bound testosterone. J Clin Endocrinol Metab, 1985. 61(4): p. 705-10.
18. Forker, E.L., et al., Effect of albumin binding on the hepatic transport of rose bengal: surface-mediated dissociation of limited capacity. J Pharmacol Exp Ther, 1982. 223(2): p. 342-7.
19. Bipath, P.a.M.V., Tryptophan and the kynurenine pathway in haemodialysis and peritoneal dialysis. Biomedical Research, 2010. 09(April).
2. Vanholder, R., et al., Uremic toxicity: present state of the art. Int J Artif Organs, 2001. 24(10): p. 695-725.
3. Yao, K., et al., Tryptophan metabolism in animals: important roles in nutrition and health. Front Biosci (Schol Ed), 2011. 3: p. 286-97.
4. Pawlak, K., et al., Kynurenine, quinolinic acid--the new factors linked to carotid atherosclerosis in patients with end-stage renal disease. Atherosclerosis, 2009. 204(2): p. 561-6.
5. Oxenkrug, G.F., Metabolic syndrome, age-associated neuroendocrine disorders, and dysregulation of tryptophan-kynurenine metabolism. Ann N Y Acad Sci, 2010. 1199: p. 1-14.
6. Nguyen, N.T., et al., Aryl hydrocarbon receptor and kynurenine: recent advances in autoimmune disease research. Front Immunol, 2014. 5: p. 551.
7. Kawasaki, H., et al., A tryptophan metabolite, kynurenine, promotes mast cell activation through aryl hydrocarbon receptor. Allergy, 2014. 69(4): p. 445-52.
8. Shivanna, S., et al., The Aryl Hydrocarbon Receptor is a Critical Regulator of Tissue Factor Stability and an Antithrombotic Target in Uremia. J Am Soc Nephrol, 2016. 27(1): p. 189-201.
9. Shashar, M., J. Francis, and V. Chitalia, Thrombosis in the uremic milieu--emerging role of "thrombolome". Semin Dial, 2015. 28(2): p. 198-205.
10. Pawlak, D., et al., Accumulation of toxic products degradation of kynurenine in hemodialyzed patients. Int Urol Nephrol, 2001. 33(2): p. 399-404.
11. Itoh, Y., et al., Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production. Anal Bioanal Chem, 2012. 403(7): p. 1841-50.
12. Chen, Y., et al., RRLC-MS/MS-based metabonomics combined with in-depth analysis of metabolic correlation network: finding potential biomarkers for breast cancer. Analyst, 2009. 134(10): p. 2003-11.
13. EMA. Guidance for industry: bioanalytical method validation. US Department of health and human service, US FDA, Rockville, MD USA. .
14. Zhu, W., et al., Quantitative profiling of tryptophan metabolites in serum, urine, and cell culture supernatants by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem, 2011. 401(10): p. 3249-61.
15. Fuertig, R., et al., LC-MS/MS-based quantification of kynurenine metabolites, tryptophan, monoamines and neopterin in plasma, cerebrospinal fluid and brain. Bioanalysis, 2016. 8(18): p. 1903-17.
16. Meyer, T.W., et al., The clearance of protein-bound solutes by hemofiltration and hemodiafiltration. Kidney Int, 2005. 68(2): p. 867-77.
17. Manni, A., et al., Bioavailability of albumin-bound testosterone. J Clin Endocrinol Metab, 1985. 61(4): p. 705-10.
18. Forker, E.L., et al., Effect of albumin binding on the hepatic transport of rose bengal: surface-mediated dissociation of limited capacity. J Pharmacol Exp Ther, 1982. 223(2): p. 342-7.
19. Bipath, P.a.M.V., Tryptophan and the kynurenine pathway in haemodialysis and peritoneal dialysis. Biomedical Research, 2010. 09(April).
Article Sidebar
Published
Jul 31, 2017
Article Details
How to Cite
1.
Zhang A, Rijal K, Ng SK, Ravid K, Chitalia V. A mass spectrometric method for quantification of tryptophan-derived uremic solutes in human serum. J Biol Methods [Internet]. 2017 Jul. 31 [cited 2024 Apr. 25];4(3):e75. Available from: https://jbmethods.org/index.php/jbm/article/view/182
Issue
Section
Articles
Authors who publish with JBM agree to the following terms:
- Authors retain copyright and grant JBM right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
